|
Malignant neoplasm of pancreas
|
0.320 |
Biomarker
|
disease |
BEFREE |
This study suggests that gene therapy with SSTR-1 may be a potential adjuvant treatment for pancreatic cancer.
|
18823376 |
2008 |
|
Malignant neoplasm of pancreas
|
0.320 |
Biomarker
|
disease |
CTD_human |
Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia.
|
17625444 |
2007 |
|
Malignant neoplasm of pancreas
|
0.320 |
Biomarker
|
disease |
BEFREE |
SSTR-2, SSTR-5, and SSTR-1 are thought to play major roles in inhibiting pancreatic cancer growth both in vitro and in vivo.
|
15706439 |
2005 |
|
Neuroendocrine Tumors
|
0.310 |
Biomarker
|
group |
BEFREE |
Analysis of mRNA expression of the SSTR subtypes showed that SSTR2 and SSTR5 were expressed in all of the studied NETs; SSTR1 and SSTR4 in all but 3 tumors (86%); and SSTR3 in only 10 NETs (49%).
|
20423238 |
2010 |
|
Pancreatic Neoplasm
|
0.310 |
AlteredExpression
|
disease |
LHGDN |
Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer.
|
18823376 |
2008 |
|
Pancreatic Neoplasm
|
0.310 |
Biomarker
|
disease |
CTD_human |
Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia.
|
17625444 |
2007 |
|
Neuroendocrine Tumors
|
0.310 |
Biomarker
|
group |
CTD_human |
Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia.
|
17625444 |
2007 |
|
Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
SSTR1 and SSTR4 immunoreactivities were increased in the hippocampus at 1 week after SE.
|
18951627 |
2009 |
|
Petit mal status
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Grand Mal Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Complex Partial Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Status Epilepticus, Subclinical
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Non-Convulsive Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Simple Partial Status Epilepticus
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Pituitary and hypothalamic somatostatin receptor subtype messenger ribonucleic acid expression in the food-deprived and diabetic rat.
|
7956902 |
1994 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We studied the immunohistochemical expression of SSTR1-5 in 151 primary tumors, including 14 metastasized and 16 SDHB-deficient tumors.
|
30529752 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SSTR1 to SSTR5 expression in PC tumors.
|
30657933 |
2019 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
SSTR1 hypermethylation in 64% of cases was correlated with tumor size (P = 0.037), stage (P = 0.037), SST methylation (P < 0.001), and expression of galanin (P = 0.03), GALR2 (P = 0.014), TAC1 (P = 0.023), and tachykinin receptor type 1 (TACR1) (P = 0.003).
|
25734919 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
DR2 was expressed in 74% and co-expressed with SSTR1 in 56%, with SSTR2A in 59%, with SSTR3 in 19%, and with SSTR5 in 37% of the tumors.
|
25765100 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A total of 240 formalin-fixed, paraffin-embedded tumour samples from 90 patients with bronchopulmonary NEN were examined by IHC and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) for SSTR1, 2A, 3, 4 and 5 expression.
|
25641082 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The multiligand SOM230 (pasireotide) displays a much higher affinity for SSTR1 and SSTR5 than octreotide and suppresses ACTH secretion in cultures of human corticotroph tumors to a greater extent than octreotide.
|
25011056 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In contrast, ectopic expression of SSTR1 in gastric cancer cell lines (MKN28 and MGC803) significantly suppressed cell growth in culture conditions and reduced tumour size in nude mice.
|
23722468 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunoreactivity of sstr1, sstr2a and sstr4 tended to decrease as tumor aggressiveness increased. sstr5 showed an opposite pattern, with higher staining in well-differentiated carcinomas compared with well-differentiated tumors. sstr5 immunoreactivity was correlated with the presence of metastases and angioinvasion, suggesting a possible association with more aggressive behavior.
|
22156600 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Analysis of mRNA expression of the SSTR subtypes showed that SSTR2 and SSTR5 were expressed in all of the studied NETs; SSTR1 and SSTR4 in all but 3 tumors (86%); and SSTR3 in only 10 NETs (49%).
|
20423238 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The overexpression of SSTR-1 significantly inhibited subcutaneous tumor size by 71% and 43% (n = 5, P < 0.05, Student's t-test), and inhibited tumor weight by 69% and 47% (n = 5, P < 0.05, Student's t-test), in Panc-SSTR-1 and MIA-SSTR-1 groups, respectively, indicating the potent inhibitory effect of SSTR-1 on pancreatic cancer growth.
|
18823376 |
2008 |